Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Background: TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enhanced the antitumor effect of temozolomide regardl...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Coyne, Geraldine O'Sullivan, Kummar, Shivaani, Meehan, Robert S., Do, Khanh, Collins, Jerry M., Anderson, Larry, Ishii, Kazusa, Takebe, Naoko, Zlott, Jennifer, Juwara, Lamin, Piekarz, Richard, Streicher, Howard, Sharon, Elad, Rubinstein, Larry, Voth, Andrea Regier, Lozier, Jay, Dull, Angie B., Wilsker, Deborah, Hinoue, Toshinori, Laird, Peter W., Ferry-Galow, Katherine V., Kinders, Robert J., Parchment, Ralph E., Doroshow, James H., Chen, Alice P.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2020
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646836/
https://ncbi.nlm.nih.gov/pubmed/33216844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27784
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares